Skip to main content
Clinical Trials/NCT04695886
NCT04695886UnknownNot Applicable

Evaluation of the Effectiveness and Cost-effectiveness of a Community-delivered Integrated Malaria Elimination (CIME) Model in Myanmar: An Open Stepped-wedge Cluster-randomised Controlled Trial

Macfarlane Burnet Institute for Medical Research and Public Health Ltd0 sites6,440 target enrollmentStarted: January 1, 2021Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Sponsor
Enrollment
6,440
Primary Endpoint
Blood examination rate

Study Overview

Brief Summary

In Myanmar, community health workers, known as malaria volunteers, have played a key role in reducing the malaria burden in the malaria control phase, providing essential malaria services in rural areas where the coverage of formal health services is limited. However, the community-delivered models that have worked well for malaria control may not work well for malaria elimination. In parallel with switching from interventions for malaria control to those for elimination, the motivation and social importance of malaria volunteers has declined along with the decline of the malaria burden. To sustain volunteer motivation, the social importance and effectiveness in the malaria elimination program, the Community-delivered Integrated Malaria Elimination model for Myanmar (CIME model) was developed based on global evidence and qualitative consultations with community members, leaders, volunteers and health stakeholders in Myanmar. This study will assess the level of effectiveness of the CIME model in increasing malaria testing by its application in an open cluster-randomised controlled stepped-wedge trial.

Detailed Description

The CIME model integrates interventions for malaria, dengue, tuberculosis, childhood diarrhoea and Rapid Diagnostic Test (RDT)-negative fever. It will involve the recruitment and training of a volunteer to implement the CIME model in each village.

The primary outcome of the trial is blood examination rate as determined by number of RDTs for malaria performed per week per village. 140 villages in 8 townships across Ayeyarwaddy, Bago and Yangon Regions and Kayah State in Myanmar will be sampled at random with probability proportional to size. Study populations include villages with ICMVs who will be re-trained as CIME volunteers (intervention phase) and the community members in the service catchment areas of those volunteers. An open stepped-wedge cluster-randomised controlled trial, randomized at the volunteer level (i.e. the volunteer and the village / workplaces they service), will be conducted over 6-months to evaluate the effectiveness and cost-effectiveness of the CIME model intervention. The stepped-wedge design will comprises 24 weekly measurements of the number of malaria blood examinations performed by each village, with villages grouped into 10 blocks of 14 villages and transitioned from control to intervention phases at bi-weekly intervals following a universal two-week control period. Differences in the per weekly rate of blood examination (primary outcome), will be estimated across intervention and control phases using a generalised linear (e.g. Poisson or negative-binomial link functions) mixed modelling analytical approach with maximum likelihood estimation.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Crossover
Primary Purpose
Health Services Research
Masking
None

Eligibility Criteria

Sex
All
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • Villages in Ayeyarwaddy, Bago and Yangon Regions and Kayah State townships in Myanmar with National Malaria Control Program (NMCP) trained Integrated Community Malaria Volunteers (ICMVs).

Exclusion Criteria

  • Townships
  • A township will be excluded from the study if:
  • The township does not have an NMCP provided ICMV network
  • The township has ongoing armed conflict
  • The township does not have Vector-Borne Diseases Control (VBDC) staff or malaria focal person
  • The location of the township is not geographically or politically feasible for staff from the State/Regional capital city to conduct regular supervision visits
  • After selection of 8 townships (2 townships from each state/region), villages in the townships will be screened against the exclusion criteria. A village will be excluded from the study if:
  • The village is too remote and unable to execute the CIME model completely,
  • The village has a government public health facility,
  • The village has no mobile network coverage
  • The village is in the ongoing armed conflict zone , or
  • The village has an ICMV program operated by any organizations other than NMCP
  • The village has an Annual Parasite Index (API) >=5

Outcomes

Primary Outcomes

Blood examination rate

Time Frame: Assessed weekly, longitudinally over 6-months

Change in blood examination rate as determined by the number of rapid diagnostic tests (RDTs) for malaria performed per week per village

Secondary Outcomes

  • Plasmodium spp. infection detected by RDT(Assessed weekly, longitudinally over 6-months.)
  • Larval source management(Assessed weekly, longitudinally over 6-months.)
  • TB DOTS(6-month)
  • Seroprevalence of malaria-associated antibodies(Assessed weekly, longitudinally over 6-months)
  • Acceptability of the CIME model by stakeholders(6-month)
  • Plasmodium spp. infections reported with 24 hours(Assessed weekly, longitudinally over 6-months.)
  • Tuberculosis (TB) cases(Assessed weekly, longitudinally over 6-months)
  • Diarrheal cases diagnosed, treated and referred(Assessed weekly, longitudinally over 6-months)
  • RDT-negative fever cases(Assessed weekly, longitudinally over 6-months)
  • Malaria treatment according to national policy(Assessed weekly, longitudinally over 6-months)
  • Plasmodium spp. infection detected by PCR(Assessed weekly, longitudinally over 6-months.)
  • Dengue cases(Assessed weekly, longitudinally over 6-months.)
  • Malaria drug resistance-associated mutations(Assessed weekly, longitudinally over 6-months)
  • Levels of malaria-associated antibodies(Assessed weekly, longitudinally over 6-months)
  • Data accuracy and completeness in reporting of malaria cases(Assessed weekly, longitudinally over 6-months)
  • Acceptability of the CIME model by villagers(6-month)
  • Acceptability of the CIME model by CIME volunteers(6-month)
  • Cost-effectiveness of the CIME model(6-month)

Investigators

Sponsor
Macfarlane Burnet Institute for Medical Research and Public Health Ltd
Sponsor Class
Other
Responsible Party
Sponsor

Similar Trials

Effectiveness of a Community-delivered... | Clinical Trial